Drug intelligence / Profile preview

MLAB-003

Development stage: Unknown
Lead developer: MLAB Biosciences
Modality: Antibody-Based Therapeutics

Overview

MLAB-003 is an investigational antibody drug developed by MLAB Biosciences. It is currently in the discovery phase and has not yet entered clinical trials. The primary therapeutic areas under investigation include nervous system diseases, congenital disorders, and skin and musculoskeletal diseases. Its most advanced indication is for muscular dystrophies. Specific details regarding its mechanism of action or molecular target have not been disclosed as of the latest update[1].

Beyond the preview

Go deeper on MLAB-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLAB-003.

Explore the full profile